Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Earl
Interview: Eco-Inject: Bringing Affordable Sustainability to Single-Use Disposable Autoinjectors
Citation: “Interview with Michael Earl and Steven Kaufman: Eco-Inject – Bringing Affordable Sustainability to Single-Use Disposable Autoinjectors”, ONdrugDelivery, Issue 191 (Oct 2026), pp 62–65.
The new and the old of business process redesign
Ayuda Buscar en la ayuda Buscar en la ayuda
CONQUERING THE CHALLENGES OF CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT
Citation: Earl M, “Conquering the Challenges of Connected Drug Delivery Device Development”. ONdrugDelivery, Issue 155 (Dec 2023), pp 28–30. Michael Earl discusses the factors that need to be taken into account for successful connected drug delivery device development.
Connecting Drug Delivery 155
Issue No #155 Dec 2023 December 13th, 2023 Inside the magazine
Connected devices: key considerations for pharmaceutical companies
The connected drug delivery device market is growing rapidly, with projections of over 20% growth in the market annually between 2023 and 2030, fuelled in part by increased self-administration outside healthcare settings. However, many pharmaceutical companies may not have a clear-cut understanding of their own and their patients’ specific needs when it comes to connected devices, and may not be used to thinking in device terms.
Connected drug delivery device development
Connected drug delivery device development - Today's Medical Developments
Column - Digitalizing Drug Delivery – What’s Next? - MedTech Intelligence
The market for connected drug delivery devices is rapidly expanding, with expectations the industry will grow by 9.1% annually until 2030.[i] Key factors driving market growth include an aging population increasingly suffering from chronic diseases and a shift towards treatment self-administration outside of a hospital setting. Connected devices already enable remote patient monitoring by collecting real-time data, such as injection date and time, and these benefits are likely to grow with time.
Michael Earl, Author at ONdrugDelivery
Privacy Overview This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
Benefits of a burgeoning partnership
Collaboration Stevanato Group and Owen Mumford Pharmaceutical Services join forces for auto-injector production. Among the learnings from the COVID-19 pandemic was the need to build more resilient supply chains. Where possible, greater collaboration between industry players is an invaluable strategy in this endeavor, allowing companies to bring their respective strengths together, and better serve their customers.
The future of patient experience: how connected drug delivery will promote inclusivity and adherence
Michael Earl, director, pharmaceutical services at Owen Mumford, examines the benefits that patients are set to receive as the connected drug delivery devices market grows. Key insights: With digitalisation, devices can support the patient during the injection procedure, by providing feedback to facilitate the rotation of injection sites, confirmation of drug delivery and injection reminders.
AREAS TO WATCH IN CONNECTED DRUG DELIVERY DEVICE DEVELOPMENT
To Issue 141 Citation: Earl M, “Areas to Watch in Connected Drug Delivery Device Development”. ONdrugDelivery, Issue 141 (Dec 2022), pp 6–8. Michael Earl identifies areas of development in the field of connected drug delivery devices, providing an insight into what can be expected in the coming years. He draws on Owen Mumford’s own research, as well as discussions with industry experts and counterparts.
The auto-injector that anticipates future trends in drug development
Michael Earl, director, Pharmaceutical Services at Owen Mumford, explains how Owen Mumford’s Covid-compliant study design and careful planning allowed them to finalise their product design and present this innovative product to the market. The platform disposable auto-injector, Aidaptus, is designed to address the priorities of both patients and pharmaceutical manufacturers. Key highlights: OM's Aidaptus introduces a consistent injection process for users.
Sustainability in pharma: how do we measure up?
The pharma sector is performing well in terms of sustainability, but as this guest blog from Owen Mumford reveals it must improve its targets for packaging and waste Add bookmark Michael Earl, Director of Pharmaceutical Services at medical device company Owen Mumford, explains that the pharmaceutical is ahead of the average in many areas of sustainability, but there are some surprising omissions.
Environment: where does the pharmaceutical industry stand?
Industry is taking environmental commitments more seriously, especially after pivotal events such as COP26 and publication of the IPCC’s cautionary ‘now or never’ report. Pharma is no exception, with some of the biggest companies making impressive strides in recent years.
SUPPORTING PATIENTS ON THE ROAD TO SELF-CARE
To Issue 134 Citation: Earl M, “Supporting Patients on the Road to Self-Care”. ONdrugDelivery, Issue 134 (Jun 2022), pp 80–82. Michael Earl discusses the importance of transitioning current healthcare models to embrace patient self-management and how advanced drug delivery device technologies, such as connectivity, can ease this burden on overstretched healthcare services.
Making progress towards sustainability
Michael Earl, director, Pharmaceutical Services at Owen Mumford describes the steps the industry has taken so far in relation to sustainability and the remaining possibilities. The pharmaceutical industry has an important role to play as the world strives to create a more sustainable future. The significance of big pharma’s impact is highlighted by the fact it produces 13% more carbon emissions than car manufactures do assembling vehicles.
A CHECKLIST FOR AUTOINJECTOR DESIGN
To Issue 133 Citation: Earl M, “A Checklist for Autoinjector Design”. ONdrugDelivery, Issue 133 (May 2022), pp 76–78. Michael Earl outlines the five key questions autoinjector designers typically ask during the development process and the choices available for tailoring autoinjector products.
Injectable Drug Delivery: Formulations & Devices133
Issue No #133 May 2022 May 12th, 2022 Inside the magazine Top This website uses functional cookies (but not advertising cookies). View our Privacy Policy.
SO FAR SO GOOD: MAINTAINING THE MOMENTUM OF PROGRESS FOR SUSTAINABLE POLICIES
To Issue 129 Citation: Earl M, “So Far So Good: Maintaining the Momentum of Progress for Sustainable Policies”. ONdrugDelivery Issue 129 (Feb 2022), pp 40–42. Michael Earl discusses the highlights of a review undertaken by Owen Mumford into how the pharmaceutical industry is faring on environmental, social and governance standards, noting that while the industry is performing above average overall, there remain some key areas for improvement.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack